How life sciences regulation is shifting in 2026

Life sciences regulation is moving on several fronts in 2026. Across major markets, agencies are clarifying how sponsors may use confirmatory evidence, established knowledge, modeling and non-animal methods. Governments are also revising development and approval frameworks as they seek to attract innovative products and clinical research.

These changes do not amount to a single, coordinated shift. Some are contained in draft guidance. Others have been politically agreed but are not yet in force. Several reflect policies introduced earlier that are only now beginning to affect development decisions.

Taken together, however, they point in a consistent direction: regulators are creating more scope to consider different forms of evidence and established knowledge, provided sponsors can demonstrate their scientific relevance, reliability and applicability to the product under review.

This article summarizes the position as of 17 July 2026.

Key takeaways

United States: FDA is providing more detail on how one adequate and well-controlled investigation may be supported by confirmatory evidence, while advancing the use of established knowledge, modeling and non-animal methods.
European Union: The EU Pharmaceutical Package has been politically agreed but is not yet in force. Its provisions would shorten active assessment timelines, restructure regulatory protection and introduce new mechanisms for complex and platform-based products.
EU market access: Joint Clinical Assessment is already operating for oncology medicines and advanced therapies and is beginning to scale, bringing comparative evidence requirements earlier into development.
United Kingdom: The UK remains outside the EU Joint Clinical Assessment framework and retains separate regulatory and health technology assessment processes.
Japan: Reforms are intended to reduce drug lag and drug loss, strengthen conditional approval and support earlier Japanese participation in global development.
China: Revised implementing regulations took effect on 15 May 2026, strengthening the legal basis for expedited pathways, lifecycle accountability and specified innovation incentives.

United States: FDA guidance broadens the evidence discussion

One of the most consequential US developments concerns how evidence of effectiveness may be assembled.

In revised draft guidance, FDA explains more fully how one adequate and well-controlled clinical investigation, supported by confirmatory evidence, may meet the substantial-evidence standard. The guidance discusses potential sources of confirmatory evidence including related clinical data, mechanistic evidence, natural-history information and real-world data.

This does not change the statutory standard, nor does it establish a general one-trial route to approval. FDA has long had flexibility to accept one adequate and well-controlled investigation with confirmatory evidence. The 2026 draft provides a more consolidated account of how that flexibility may be applied and emphasizes that the strength of the complete evidence package remains product- and context-dependent.

For individualized therapies targeting genetic conditions with a known biological cause, FDA’s draft sets out an approach for generating evidence where conventional randomized trials may not be feasible. The framework considers the biological cause of disease, the therapy’s proposed mechanism, natural-history data, evidence of successful target engagement or editing, and relevant clinical outcomes or biomarkers.
It is a proposed evidentiary framework, not a new statutory approval pathway. Sponsors must still provide sufficient evidence of safety and effectiveness and demonstrate that the therapy can be manufactured to the required quality standards.

A separate draft guidance on leveraging prior knowledge concerns gene therapies incorporating genome editing. It describes how sponsors may draw on relevant public and platform knowledge across chemistry, manufacturing and controls, nonclinical studies and clinical development, rather than regenerating the same information for each program.

Sponsors would still need to demonstrate that the prior knowledge is scientifically applicable to the specific product.

“The direction from FDA is not towards a lower evidentiary standard, but towards a more considered use of the evidence already available. Sponsors still need to show that each source of data is relevant, reliable and applicable to the product. That makes the coherence of the overall evidence package—and early dialogue with the agency—more important, not less.”
Dr Mamta Puri-Lechner
Head of Regulatory, United States, VCLS

Non-animal methods and model-informed development

FDA is also giving greater attention to new approach methodologies.

Its March https://www.fda.gov/news-events/press-announcements/fda-releases-draft-guidance-alternatives-animal-testing-drug-development provides a general validation framework for methods submitted in support of drug development. Examples include organoids, spheroids, organs-on-chips and in silico models.

The intention is to support reliable, human-relevant methods where they can improve the predictive value of nonclinical evidence and reduce or replace some animal studies. The draft guidance does not provide automatic acceptance of any particular method; sponsors must establish its reliability and scientific validity for its proposed use.

In June, FDA accepted the first Letter of Intent for an in silico drug-development tool into its ISTAND qualification program. The AI-driven digital liver model is intended to support assessment of drug-induced liver-injury risk for small-molecule candidates.

Acceptance of the Letter of Intent begins the qualification process. It does not mean that the tool is already qualified for a defined regulatory context of use.

This development is distinct from the organ-on-a-chip liver technology accepted into the ISTAND pilot in 2024. The two developments illustrate different approaches to improving the prediction of human toxicity, but neither should be interpreted as broad regulatory acceptance of an entire class of tools.
Further FDA activity includes final ICH M15 guidance on model-informed drug development, draft guidance on quantitative systems pharmacology-based dose selection for minimum anticipated biological effect level, and draft guidance on Bayesian methodology.

Together, these documents give sponsors additional direction on using modeling and prior information in early-phase, adaptive and confirmatory development.

Several of these initiatives were brought together or highlighted under Operation TrialBlazer, announced by the US Department of Health and Human Services in June 2026. Its proposed measures include a voluntary pilot intended to shorten the path from drug identification to first-in-human studies, clarification of phase-appropriate requirements and further support for early clinical development in the United States.

European Union: the Pharmaceutical Package is not yet in force

The EU Pharmaceutical Package is expected to deliver the largest overhaul of European medicines legislation in more than two decades. The European Parliament and Council reached provisional political agreement in December 2025. EU Member States’ representatives endorsed the compromise texts in March 2026, followed by approval in the relevant European Parliament committee.

As of 17 July 2026, however, formal adoption and publication have not taken place. The legislation remains close to adoption, with the remaining institutional steps expected later in 2026.

A two-year transition is expected after the legislation enters into force, with most substantive provisions therefore likely to apply from around 2028. The agreed texts show the intended direction of the reform rather than requirements that sponsors must follow today.

Under the agreed texts, the standard EMA scientific assessment timetable would fall from 210 to 180 active days, excluding clock stops. A 150-day timetable would apply to certain products of major public-health interest. The reform would also simplify EMA’s committee structure and seek to reduce procedural complexity. These targets refer to active scientific-assessment time. They should not be interpreted as the complete elapsed time from submission to authorization, which may also include clock stops and the European Commission decision-making stage.

The system of regulatory protection would also change. The agreed model retains a standard eight-year period of data protection, with market protection and potential extensions structured around specified conditions.

The legislation would introduce regulatory sandboxes into EU pharmaceutical law. These supervised environments are intended for products that cannot be developed effectively under existing requirements, with potential applications including advanced therapies, personalized medicines and AI-enabled products.

It would also introduce platform technology master files for human medicines. A reusable technological “backbone” could be assessed in a standalone dossier and subsequently referenced by multiple product applications, subject to regulatory agreement and future implementing guidance.

The concept builds on EMA’s experience with platform technology master files for veterinary vaccines.
The Pharmaceutical Package is only one part of the changing European environment. The proposed Critical Medicines Act, the planned Biotech Act and stronger shortage and environmental-risk obligations are widening the policy and compliance picture beyond the marketing-authorization procedure. Several of these measures remain under development or negotiation.

EU market access: Joint Clinical Assessment scales up

Unlike the Pharmaceutical Package, the EU Health Technology Assessment Regulation is already applicable. Since January 2025, Joint Clinical Assessment has applied to new oncology medicines and advanced therapy medicinal products within scope.

Activity is increasing during 2026, and the first selected high-risk medical devices and class D in vitro diagnostics can begin entering the process. Device and diagnostic assessments apply only to eligible products selected under the relevant procedure; they are not automatic for every product in those classes.

Orphan medicines are due to enter scope in 2028, followed by all centrally authorized medicines in 2030.
A JCA assesses relative clinical effectiveness and safety at EU level. It does not determine price, reimbursement, cost-effectiveness or final market-access decisions, which remain national responsibilities. EU Member States must take the joint report into account but may still require additional evidence for aspects of their national appraisal.

The timing has practical implications for sponsors. The approximately 90-day period between confirmation of the assessment scope and dossier submission leaves little opportunity to resolve major evidence gaps late in the process.

Early implementation experience has also highlighted questions about the transferability of evidence, including the relevance of trial populations, comparators and standards of care to European decision-making.

Regulatory approval and market-access evidence can therefore no longer be planned as fully sequential workstreams. Comparative-effectiveness expectations need to be considered while clinical programs and evidence-generation plans are still being designed.

United Kingdom: MHRA regulation and separate UK HTA processes

The United Kingdom continues to develop a distinct regulatory and market-access framework.
In June, the MHRA and FDA announced a https://www.gov.uk/government/news/unique-liaison-programme-set-to-reinforce-close-collaboration-between-mhra-and-fda. Dedicated liaison roles are intended to support closer scientific exchange and day-to-day collaboration on medicines, medical devices and emerging technologies, including AI.

The two agencies retain regulatory independence and will continue to make separate decisions.
The MHRA is also developing its approach to AI in healthcare through its National Commission into the Regulation of AI in Healthcare, a completed call for evidence and its AI Airlock regulatory sandbox.
This work reflects the need for more dynamic, lifecycle-based approaches as AI-enabled technologies are incorporated into healthcare products and systems.

The UK is not part of the EU Joint Clinical Assessment framework. It retains separate national HTA processes, including those led by NICE and the Scottish Medicines Consortium.

Sponsors developing products for both the EU and UK must therefore plan for potential differences in assessment scope, evidence requirements, timing and decision-making.

Japan: PMD Act reform and the effort to reduce drug loss

Japan’s recent reforms respond to a well-defined challenge: innovative medicines approved elsewhere may reach Japanese patients later than patients in other major markets, or may not be developed in Japan at all.

Amendments to the Pharmaceuticals and Medical Devices Act, enacted in 2025 and being implemented through 2026, strengthen the conditional-approval framework. The revised approach includes clearer post-approval evidence obligations and the possibility of modifying or revoking an approval when those obligations are not fulfilled.

The amendments also strengthen the focus on pediatric development planning. Applicants are expected to make best efforts to consider pediatric development, supported by updated PMDA and Ministry of Health, Labour and Welfare notifications and opportunities for regulatory consultation.
This is not an absolute mandatory planning requirement equivalent to the EU Paediatric Investigation Plan system.

More broadly, Japan is working to reduce duplicative local development requirements and encourage earlier participation in global programs. These measures build on the December 2023 relaxation of the general expectation for Japanese Phase I data before Japanese participants can enter multiregional clinical trials.

Product-specific scientific considerations, including ethnic sensitivity and available safety information, continue to apply.

Japan has also required eCTD v4.0 for relevant new drug applications since April 2026, placing it ahead of other major markets in mandatory implementation. For global submission teams, this has immediate implications for publishing infrastructure, metadata management and lifecycle planning.

PMDA provides the relevant notifications and technical materials through its eCTD v4 information page.

China: revised Drug Administration Law regulations take effect

China’s revised Implementing Regulations of the Drug Administration Law were promulgated on 27 January 2026 and took effect on 15 May 2026. They represent the first comprehensive overhaul of the implementing provisions in more than two decades.

The regulations place four established expedited mechanisms on a stronger legal footing:

breakthrough therapy;
conditional approval;
priority review; and
special approval.

These mechanisms are not new, having previously operated under NMPA departmental rules, but their inclusion in the revised regulations provides a more substantial administrative-law basis.
The regulations also introduce a dedicated marketing-authorization-holder chapter and reinforce product-lifecycle accountability.

Qualifying pediatric medicines may receive up to two years of market exclusivity, while qualifying orphan drugs may receive up to seven years, subject to a commitment to maintain supply.

The regulations establish a stronger basis for protecting independently obtained, undisclosed trial data, including protection of up to six years for eligible products containing new chemical entities. Further NMPA implementation detail will remain important in determining how these provisions operate in practice.

The regulations also confirm that qualifying overseas research data may support a Chinese registration application.

The reforms must be viewed against China’s continuing access gap. One study of 327 new drugs approved by FDA between 2012 and 2019 found that 41.3% had been authorized in China by November 2023. The same analysis associated the inclusion of mainland Chinese sites in pivotal trials with faster entry into the Chinese market.

For sponsors, the direction favors earlier engagement with the NMPA and deliberate consideration of Chinese participation in global clinical development. The appropriate strategy will still depend on the product, indication, evidence package and commercial priorities.

What the 2026 regulatory changes mean for sponsors

Across these markets, regulators are creating more scope to consider confirmatory evidence, established knowledge, modeling, alternative methods and overseas data.

This does not amount to a general lowering of evidentiary standards. In many cases, greater flexibility places more responsibility on the sponsor to explain why a particular source, model or method is reliable and relevant to the product under review. A single investigation, external dataset, platform precedent or non-animal method will only be persuasive when it forms part of a scientifically coherent evidence package.

The more immediate challenge for global programs is coordination. An approach designed around one regulator’s flexibility may leave evidence gaps elsewhere.

In Europe, market-access evidence requirements are moving closer to the clinical-development timetable. The UK retains separate assessment processes, while Japan and China are changing their frameworks on different schedules.

The practical priority is therefore not to pursue the fastest route in each market independently. It is to understand:

where evidence can be used across jurisdictions;
where local evidence or procedural requirements remain;
how regulatory flexibility in one market may be viewed elsewhere;
when comparative and market-access evidence needs to be generated; and
how regional submissions should be sequenced within the global development plan.

These are strategic development questions well before they become submission questions.

Frequently asked questions

Does FDA now approve drugs on the basis of a single clinical trial?
Not automatically. FDA has long had statutory flexibility to accept one adequate and well-controlled investigation supported by confirmatory evidence. Its 2026 revised draft guidance provides more detail on when this approach may be appropriate and what sources may contribute to the confirmatory evidence. The complete evidence package must still satisfy the statutory substantial-evidence standard, and the guidance is not yet final.
Is the EU Pharmaceutical Package in force?
No. As of 17 July 2026, the European Parliament and Council have reached provisional political agreement, but formal adoption and publication are still required. The remaining institutional steps are expected later in 2026. Most substantive provisions are then expected to apply after a two-year transition.
Does EU Joint Clinical Assessment determine pricing and reimbursement?
No. JCA assesses relative clinical effectiveness and safety at EU level. Pricing, reimbursement, economic evaluation and final market-access decisions remain national responsibilities.
Is the UK included in EU Joint Clinical Assessment?
No. The UK sits outside the EU framework and retains separate national HTA processes, including those led by NICE and the Scottish Medicines Consortium. Sponsors still need to plan for UK assessment even where a product has undergone EU-level Joint Clinical Assessment.
What is FDA’s Plausible Mechanism Framework?
It is a proposed evidentiary approach for individualized therapies targeting specific genetic conditions with a known biological cause. The framework is intended for circumstances in which a conventional randomized trial may not be feasible. It is not a new statutory approval pathway. Sponsors must still provide the evidence needed to satisfy existing requirements for safety, effectiveness and product quality.
When did China’s revised drug regulations take effect?
The revised Implementing Regulations of the Drug Administration Law took effect on 15 May 2026, following their promulgation on 27 January. They strengthen the legal basis for established expedited pathways, lifecycle accountability and specified innovation incentives.
What should global sponsors do differently?
Regulatory, clinical and market-access evidence requirements should be assessed together and earlier in development. Greater flexibility in one jurisdiction does not mean that the same evidence package will meet the expectations of another regulator or HTA body. Early cross-functional planning can help identify where evidence may be reused, where local evidence remains necessary and where regulatory and market-access expectations need to be addressed before the pivotal program is fixed.

Planning a global development program? VCLS helps biotech, pharmaceutical and MedTech teams align regulatory strategy, clinical research, evidence generation and market-access requirements across major markets.

Our teams support clients in assessing regional evidence expectations, identifying opportunities to use established knowledge and alternative evidence sources, planning authority interactions, and coordinating development and access strategy across jurisdictions.

Discuss your development program with VCLS

Selected primary sources

United States
- US Food and Drug Administration. Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Draft Guidance for Industry. June 2026.
- US Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific. February 2026.
- US Food and Drug Administration. Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing: Draft Guidance for Industry. June 2026.
- US Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-releases-draft-guidance-alternatives-animal-testing-drug-development. March 2026.
- US Food and Drug Administration. FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury. 3 June 2026.
- US Food and Drug Administration. M15 General Principles for Model-Informed Drug Development. June 2026.
- US Food and Drug Administration. Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry. January 2026.
- US Department of Health and Human Services. HHS Launches Department-Wide Effort to Restore American Leadership in Clinical Trials. 22 June 2026.
- US Department of Health and Human Services. Operation TrialBlazer: HHS Roadmap to Maintaining US Leadership in Early Clinical Research and Development. 2026.
European Union
- European Medicines Agency. Reform of EU Pharmaceutical Legislation.
- Council of the European Union. https://www.consilium.europa.eu/en/press/press-releases/2025/12/11/pharma-package-council-and-parliament-reach-a-deal-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector/. 11 December 2025; updated 6 March 2026.
- European Parliament. Revision of the EU Pharmaceutical Legislation. Status updated 20 June 2026.
- European Commission. Reform of EU Pharmaceutical Legislation.
- European Medicines Agency and European Commission. https://www.ema.europa.eu/en/documents/presentation/presentation-session-1-provisions-new-eu-pharmaceutical-legislation-platform-approaches-f-schmidt_en.pdf. March 2026.
- European Commission. Joint Clinical Assessments.
- European Commission. https://health.ec.europa.eu/health-technology-assessment_en.
- European Commission. https://health.ec.europa.eu/publications/guidance-htacg-recommendation-selection-medical-devices-and-vitro-diagnostic-medical-devices-jca_en. 28 November 2025.
United Kingdom
- Medicines and Healthcare products Regulatory Agency. https://www.gov.uk/government/news/unique-liaison-programme-set-to-reinforce-close-collaboration-between-mhra-and-fda. 15 June 2026.
- Medicines and Healthcare products Regulatory Agency. Regulation of AI in Healthcare: Call for Evidence Outcome. Updated 11 June 2026.
- Medicines and Healthcare products Regulatory Agency. National Commission into the Regulation of AI in Healthcare.
- Medicines and Healthcare products Regulatory Agency. Advancing AI Regulation in Healthcare: Insights from AI Airlock Phase 2. 9 June 2026.
Japan
- Pharmaceuticals and Medical Devices Agency. Pediatric and Orphan Drugs: Regulations and Notifications.
- Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/files/000280947.pdf.
- Pharmaceuticals and Medical Devices Agency. eCTD Version 4 Series.
- Pharmaceuticals and Medical Devices Agency. ICH Electronic Common Technical Document v4.0 Implementation Guide in Japan, Version 1.6.0. March 2025.
China
- National Medical Products Administration. https://english.nmpa.gov.cn/2026-01/28/c_1157477.htm. 28 January 2026.
- State Council of the People’s Republic of China. https://english.www.gov.cn/policies/latestreleases/202601/27/content_WS6978a68ec6d00ca5f9a08c79.html. 27 January 2026.
Supporting research
- Zhu X, Chen Y. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1296737/full. Frontiers in Pharmacology. 2024;14:1296737

VCLS (Voisin Consulting Life Sciences) is a specialist life sciences product development partner helping biotech, pharmaceutical and MedTech innovators advance complex products through regulated development and toward patient access.

This article reflects developments and information available as of 17 July 2026. Several measures discussed remain in draft, await formal adoption or require implementing guidance. Current requirements should therefore be confirmed when planning a specific development program.